BNT162a1 SARS-CoV-2 Vaccine

BNT162a1 SARS-CoV-2 Vaccine Uses, Dosage, Side Effects, Food Interaction and all others data.

BNT162a1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech. BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.

BNT162a1 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).

Trade Name BNT162a1 SARS-CoV-2 Vaccine
Generic BNT162a1 SARS-CoV-2 Vaccine
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
BNT162a1 SARS-CoV-2 Vaccine
BNT162a1 SARS-CoV-2 Vaccine

Innovators Monograph

You find simplified version here BNT162a1 SARS-CoV-2 Vaccine


*** Taking medicines without doctor's advice can cause long-term problems.
Share